Trastuzumab in the adjuvant setting: Concurrent or sequential? It takes two to tango!

Current Oncology

Volumn 15, Issue 1, 2008, Pages 66-67

  Verma, Sunil ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; BREAST BIOPSY; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER STAGING; CASE REPORT; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PARTIAL MASTECTOMY; PHYSICAL EXAMINATION; SCINTIMAMMOGRAPHY;

EID: 51649100267     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2008.204     Document Type: Editorial

References (4)

1. Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol 2008;15(suppl 1):S16-29.
2. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; [Epub ahead of print].
3. Spielmann M, Roché H, Humblet Y, et al. 3-Year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial [abstract 72]. Breast Cancer Res Treat 2007;106 (Suppl 1):.
4. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.